Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyAetna Bronchial Thermoplasty Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0744

    Bronchial Thermoplasty

    Customize your policy alerts

    Sign up for Aetna Policy 0744 alerts

    Get alerted when Policy 0744 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for bronchial thermoplasty for asthma and other indications, describing that BT is considered experimental/investigational because effectiveness has not been established; applies to adult asthma care and related procedures.

    Policy Summary
    PayerAetna
    PolicyBronchial Thermoplasty
    Policy CodePolicy 0744
    Change TypeRoutine review — no material change
    Effective DateFeb 8, 2008
    Last ReviewOct 6, 2023
    Next Review DateAug 8, 2024
    Key ActionPrior authorization should confirm adult status, severe persistent asthma despite optimized therapy, and specialist-center evaluation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3RCTs
    288AIR2 enrollment
    32%Reduction in severe exacerbations (AIR2)
    6/100Additional hospitalizations during treatment
    10/06/2023Policy last reviewed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Bronchial Thermoplasty

    Experimental/Investigational (Not Covered)

    Aetna coverage determination: Bronchial thermoplasty is considered experimental and investigational for the treatment of asthma and other indications (e.g., COPD) because effectiveness has not been established.

    Coverage = not covered for these indications per policy statement.

    Initial therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Age: Patient is an adult (≥18 years)>=18 years

    Supported by FDA approval and trial populations

    Disease severity and prior therapy: Severe persistent asthma not adequately controlled despite optimized therapy including inhaled corticosteroids and long-acting beta-agonists (documented trial of high-dose ICS + LABA or equivalent Step 4–5 therapy)documented trial of high-dose ICS + LABA or step 4–5 therapy

    FDA indication and guideline context

    Specialist evaluation: Evaluation at or referral to an asthma specialty center with multidisciplinary expertise and determination that patient is an appropriate candidatereferral documented

    Guidelines and expert reviews recommend specialist centers and experienced operators

    Contraindications absent: No active respiratory infection, no active asthma exacerbation, no coagulopathy, no recent changes to corticosteroid regimen within 14 days, no implantable electronic devices (e.g., pacemaker/ICD), and no known sensitivities to lidocaine/atropine/benzodiazepinesclinical assessment documented

    Based on product labeling, trial exclusions and policy contraindications

    Restricted/Experimental use — Use limited or considered experimental when ANY of the following are present

    Use limited or considered experimental when ANY of the following are present

    Low baseline lung function or unstable disease: Patients with low pre-bronchodilator FEV1 (below trial inclusion thresholds) or with frequent/severe exacerbations excluded from pivotal trials; generalizability and safety in these populations are uncertainFEV1 below trial-specified thresholds or frequent exacerbations beyond trial criteria

    Many trials excluded patients with FEV1 <60% (guideline note) and evidence is limited in sicker populations

    Not enrolled in registry or clinical study: Use outside an IRB-approved registry or clinical study, or without systematic long-term follow-up, is discouraged due to limited long-term sham-controlled data and potential uncommon harmsno enrollment in registry or study

    Cochrane, NICE and guideline groups advise data collection and cautious use

    Performed outside specialist centers or without governance:

    Conditional/Contextual Coverage Considerations

    Context and conditional recommendations from major guidelines and trials

    Guideline context: ERS/ATS recommend BT only in adults with severe asthma within an IRB-approved independent registry or clinical study; GINA considers BT a potential option for highly selected adults uncontrolled despite Step 5 care.

    Strong/conditional recommendations based on low-quality evidence

    Treatment effects from trials: Randomized trials (including the sham-controlled AIR2 trial) report modest improvements in quality of life and reductions in severe exacerbations and ED visits in some studies, but inconsistent effects on symptoms and pulmonary function; primary endpoints were variably met across studies.

    AIR2 showed reductions in severe exacerbations and ED visits but other measures were inconsistent

    Safety considerations: BT is associated with increased respiratory adverse events and higher hospitalization risk during the treatment period (absolute increase from ~2% to ~8%); most events are mild/moderate and transient, and long-term safety data are limited though follow-up cohorts show relative stability out to 5 years.

    Cochrane and RCT data document increased peri-procedural morbidity and limited long-term controlled data

    Initial candidate selection — Consider BT when ALL of the following are met (per guidance and expert consensus)

    Consider BT when ALL of the following are met (per guidance and expert consensus):

    Eligibility prerequisites: Severe asthma not controlled despite optimized pharmacologic therapy (including high-dose inhaled corticosteroid plus long-acting beta-agonist and other guideline-recommended add-on therapies); persistent symptoms or frequent exacerbations despite optimization; multidisciplinary specialist team deems patient appropriate for BT in a center with on-site intensive care and clinical governance arrangements.

    Expert consensus: may be considered for selected phenotypes (eg, non-TH2) after failure of triple therapy and before chronic oral corticosteroid dependence or as an alternative after inadequate response to biologics for some patients.

    Documentation of prior management: Documented history of prior maximal/optimized medical therapy, objective baseline measures (spirometry/FEV1), history of exacerbations/hospitalizations, and rationale for BT over other options (including biologics where applicable)baseline spirometry and prior therapy documented

    Registry protocols and expert panels recommend thorough documentation and phenotype assessment

    Effectiveness and safety profile — Clinical considerations and expected outcomes

    Clinical considerations and expected outcomes:

    Expected benefits and limitations: BT may lead to improvements in asthma-related quality of life and reductions in severe exacerbations and ED visits in some studies, but magnitude of benefit varies and many measures (eg, lung function, some symptom scores) did not consistently improve in sham-controlled analyses; long-term durability beyond 5 years and the ideal responder phenotype remain uncertain.

    Systematic reviews and RCTs report modest QOL gains and reductions in some healthcare utilizations but inconsistent physiologic effects

    Peri-procedural safety profile: Common adverse events in the 12-week treatment period include bronchial irritation, chest discomfort, cough, dyspnea, wheeze and increased risk of hospitalization; most events are mild/moderate and resolve within about a week, but serious events (eg, hemoptysis, infections, atelectasis) have been reported rarely.

    Cochrane and pooled RCT data document increased peri-procedural morbidity and rare serious AEs

    Long-term safety and monitoring: Available cohort and registry data suggest stability of outcomes and reduced exacerbations up to 5 years in some series, but evidence is limited and systematic long-term sham-controlled data are lacking; structured follow-up/registry reporting is advised.

    When BT is considered — Indications and specialist-setting recommendations

    BT is considered for adults with severe asthma not controlled with optimized therapy; multiple guidelines recommend use only in specialized contexts or registries.

    General selection: Adult patients (≥18 years) with severe asthma not controlled despite optimization of inhaled corticosteroids and long-acting beta-agonists, meeting ERS/ATS or GINA criteria for severe asthma, after referral to a severe asthma specialty center.age ≥18; meets severe asthma criteria per ERS/ATS or GINA

    International guidelines advise specialist referral and registry/clinical-study context

    Recommendation on context of use: When considered, BT should generally be performed within an IRB-approved registry or clinical study or with documentation to enable long-term follow-up and audit; routine use outside these contexts is not recommended.registry enrollment or documented plan for longitudinal follow-up

    ERS/ATS and GINA recommendations emphasize registry or study-based use due to limited evidence

    Bronchial thermoplasty is not intended for individuals with known sensitivities to atropine, benzodiazepines, or lidocaine, and is contraindicated for persons with implanted cardiac electronic devices such as a pacemaker or implantable cardioverter defibrillator. These device- and medication-related cautions derive from device labeling and standard procedural precautions for the Alair system and should be assessed and documented before any proposed treatment.

    Product labeling and procedural guidance specify that the Alair system is not for use in patients with pacemakers, internal defibrillators, or other implantable electronic devices. The labeling also lists patients with known sensitivities to lidocaine, atropine, or benzodiazepines as individuals who should not be treated with the device; these contraindications should be confirmed in the pre-procedure assessment.

    Clinical trial protocols and guideline summaries frequently excluded patients with chronic sinus disease, frequent chest infections, or a baseline FEV1 less than 60% predicted. These trial exclusions have been cited by guideline panels as reasons to exercise caution or to consider such populations ineligible for routine treatment outside of research settings.

    Guidance documents note that bronchial thermoplasty may be unsuitable for people with bronchiectasis and emphasize that the device is not licensed for patients younger than 18 years. Such considerations should be part of the specialist evaluation when assessing candidacy.

    Important uncertainty remains regarding the long-term safety and applicability of bronchial thermoplasty across broader severe asthma populations. Reviews and expert summaries highlight unknowns about durability of benefit, long-term adverse effects, and which phenotypes benefit most — for example, applicability in patients with FEV1 above certain thresholds or those receiving systemic steroid therapy is not well established.

    The excerpts provided from the Clinical Policy Bulletin do not list additional explicit administrative coverage exclusions beyond the clinical contraindications and trial-based exclusions noted elsewhere; the bulletin also includes administrative links and notices advising providers that the document is a partial summary of plan benefits.

    Aetna considers bronchial thermoplasty to be experimental and investigational for the treatment of asthma and other indications because effectiveness has not been established; accordingly BT is not covered as medically necessary for these indications under this policy.

    Systematic reviews, guideline assessments, and technology reviews characterize evidence for bronchial thermoplasty as showing modest benefits in some outcomes (for example, small improvements in quality of life and reductions in some exacerbation measures) but with important evidence gaps. Multiple reviews note limited trial numbers, small sample sizes, inconsistent outcome effects across studies, and concerns about long-term effectiveness and generalizability.

    Major guideline reviews and technology assessments advise caution: given the limited quantity and generally low-to-moderate quality of evidence, adoption of bronchial thermoplasty outside controlled settings is discouraged. Several reviews and guideline statements recommend that further data — particularly long-term, sham-controlled outcomes and clearer phenotype identification — are needed before routine use is warranted.

    Guidance emphasizes limits on where and by whom BT should be performed. Use of bronchial thermoplasty outside of specialist centers, without multidisciplinary specialist evaluation, or in patients who have not undergone documented optimization of medical management (including high-dose inhaled corticosteroids plus long-acting beta-agonists and other appropriate add-ons) is discouraged.

    International guideline panels recommend that when bronchial thermoplasty is used it should be performed only within an IRB-approved registry or clinical study or in the context of systematic data collection. This approach permits accumulation of longer-term safety and effectiveness data and supports careful patient selection and follow-up.

    Within the provided document excerpts there are no additional explicit statements phrased as standalone 'not medically necessary' clauses beyond the policy's overarching designation of bronchial thermoplasty as experimental/investigational; administrative notes remind readers that the bulletin is a partial description of plan benefits.

    Procedure and Diagnosis Codes

    Procedure CPT CodesCPT
    31660Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe.
    31661Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes.
    ICD-10 code ranges mentionedICD-10
    J41.0-J47.9Chronic lower respiratory diseases (including asthma).
    J67.0-J67.9Hypersensitivity pneumonitis due to organic dust.
    Coding referencedmixed
    N/ANo explicit CPT/HCPCS/ICD-10 codes were provided in this document segment; FDA approval and trial populations referenced (Alair system, adults ≥18 years).
    Pre-bronchodilator FEV1 thresholds in trials
    RISA trial long-term follow-up inclusionPre-bronchodilator FEV1 ≥ 50% predicted (RISA long-term follow-up enrolled patients with pre-bronchodilator FEV1 of 50% or more of predicted)
    AIR2 trial baseline FEV1 (population mean)Other trials enrolled patients with higher baseline FEV1 (e.g., mean ~78% in AIR2 and pivotal trial populations)
    Trial FEV1 exclusions noted in reviewsMany randomized trials excluded patients with very low FEV1; applicability to patients with FEV1 substantially below trial thresholds is uncertain

    Provider Actions, Prior Authorization, and Documentation

    Denial Risk

    Prior authorization / coverage stance

    Aetna designates bronchial thermoplasty (BT) as experimental and investigational for the treatment of asthma and other indications because its effectiveness has not been established. As a result, coverage may be denied consistent with this policy designation.

    • BT is considered experimental/investigational by Aetna for asthma and other indications.
    • Designation may lead to claim denial or requirement for exception review.
    Prior Authorization

    Registry/Study participation or specialty‑center justification

    Major international guidelines (ERS/ATS, GINA, and others) strongly recommend that BT be performed only in the context of an Institutional Review Board–approved independent registry or clinical study. Authorization decisions should recognize guideline guidance favoring registry/study participation.

    Background and Evidence Summary

    Bronchial thermoplasty is an outpatient bronchoscopic procedure that delivers controlled radiofrequency thermal energy to the airway wall to reduce airway smooth muscle mass and thereby attempt to attenuate bronchoconstriction. The Alair system applies energy via a catheter introduced through a bronchoscope, typically in a series of three outpatient sessions spaced several weeks apart; each treatment session generally takes about one hour under conscious sedation.

    Systematic reviews and major guideline assessments summarize the trial evidence as demonstrating some statistically significant but generally modest improvements in patient-reported quality of life and reductions in certain exacerbation measures; however, benefits were inconsistent across studies, did not consistently reach clinically important thresholds, and important evidence gaps remain (including small trial sizes, heterogeneous patient selection, and limited sham-controlled long-term data).

    Given the limited quantity and quality of evidence, guideline groups and technology assessments advise that bronchial thermoplasty should not be widely adopted outside controlled settings. They recommend performance within clinical studies or registries, careful patient selection, and specialist-center delivery to mitigate risks and to collect long-term outcome data.

    Definitions and Terms

    Bronchial thermoplasty (BT): key definition
    ProcedureBronchoscopic procedure that delivers controlled radiofrequency energy to airway walls to reduce airway smooth muscle mass
    Target temperatureThermoplasty catheter heats airway smooth muscle to approximately 150 degrees Fahrenheit
    IntentIntended to attenuate bronchoconstriction and reduce severe asthma attacks by ablating excess airway smooth muscle
    Bronchial thermoplasty (alternate definition)
    Alternate descriptionA novel bronchoscopic intervention that applies localized radiofrequency-generated heat via a catheter to reduce smooth muscle quantity and contractility in airway walls
    DeliveryApplied to visible proximal airways through a bronchoscope using a deployable catheter tip with multiple electrodes
    Policy Summary
    PayerAetna
    PolicyBronchial Thermoplasty
    Policy CodePolicy 0744
    Change TypeRoutine review — no material change
    Effective DateFeb 8, 2008
    Last ReviewOct 6, 2023
    Next Review DateAug 8, 2024
    Key ActionPrior authorization should confirm adult status, severe persistent asthma despite optimized therapy, and specialist-center evaluation.
    SourceLink
    On This Page
    Coverage Criteria for Bronchial ThermoplastyProcedure and Diagnosis CodesProvider Actions, Prior Authorization, and DocumentationBackground and Evidence SummaryDefinitions and Terms
    Procedures performed outside multidisciplinary specialist centers with appropriate clinical governance, training, and on-site intensive care may be considered experimental or inappropriate
    lack of specialist center documentation

    NICE and other expert panels recommend specialist-center performance and registry reporting

    Informed consent and registry participation:
    Patient provided informed consent including counseling on procedural risks and benefits, and enrollment in an IRB-approved registry or longitudinal follow-up is documented when available
    consent and registry/study enrollment or justification documented

    Guidelines and NICE recommend registry-based use or research context

    Post-approval and registry studies report up to 5-year follow-up with sustained reductions in exacerbations in observational cohorts

    • Guidelines recommend use only within IRB‑approved registries or clinical studies.
    • Clinicians and centers should document enrollment or justify participation in a specialty-center study or registry.
    Documentation Required

    Specialist center and patient‑selection documentation recommended

    The procedure should be performed only in specialist centers by clinicians trained in BT and experienced in managing severe asthma, with multidisciplinary governance and on‑site access to intensive care. Documentation of patient selection and specialist evaluation is recommended for any authorization or utilization review.

    • Multi‑disciplinary team in specialist center with on‑site intensive care required.
    • Clinician must have training/experience in BT and severe asthma management.
    • Document rationale for selecting the patient for BT, including specialist referral.
    Prior Authorization

    Prior authorization: specialist evaluation and evidence of maximal inhaled therapy

    Prior to consideration of BT, patients should have specialist evaluation confirming severe persistent asthma that remains uncontrolled despite optimized medical therapy (for example, high‑dose inhaled corticosteroid plus long‑acting beta‑agonist and other appropriate controller therapy). For some phenotypes, BT is considered after failure of optimized pharmacologic therapy (including trials of biologics where indicated) and before initiation of maintenance oral corticosteroids in selected pathways.

    • Confirm adult patient (≥18 years) with severe persistent asthma not controlled with optimized inhaled therapy.
    • Document trials of high‑dose ICS + LABA (and other controllers/biologics when appropriate) and ongoing symptoms/exacerbations.
    • State whether BT is being considered as alternative after biologic therapy failure for relevant phenotypes.
    Denial Risk

    Experimental/Investigational denial risk

    BT carries denial risk because Aetna classifies it as experimental/investigational. Even in cases where guideline contexts suggest limited use, authorization is not guaranteed.

    • Aetna’s experimental/investigational designation is an explicit ground for non‑coverage.
    • Guideline endorsement for registry‑based use does not override payer non‑coverage determinations.
    Denial Risk

    Contraindications / Denial Triggers

    Contraindications and common denial triggers that should be documented and assessed include active respiratory infection, asthma exacerbation at time of planned treatment, coagulopathy, recent changes to corticosteroid regimen (within 14 days), presence of pacemaker or implantable electronic device, known sensitivities to lidocaine, atropine, or benzodiazepines, and other exclusions used in clinical trials (e.g., frequent chest infections, bronchiectasis, low baseline FEV1 in some studies).

    • Active respiratory infection or current asthma exacerbation — exclude.
    • Coagulopathy or recent anticoagulation — exclude.
    • Pacemaker, implantable cardioverter defibrillator, or other implantable electronic devices — contraindicated.
    • Known sensitivities to lidocaine, atropine, or benzodiazepines — contraindicated.
    • Recent corticosteroid regimen changes within 14 days prior to planned treatment — contraindicated.
    Note

    Guidelines recommend BT only in the context of IRB‑approved registry/clinical study

    Guidelines emphasize caution in patient selection and recommend BT only in adults and only within IRB‑approved registries or clinical studies to accumulate long‑term safety and effectiveness data. This guideline‑recommended context may influence authorization decisions and payers may require registry/study participation or strong specialty‑center justification.

    • Recommendation: perform BT in adults only in context of IRB‑approved registry or clinical study.
    • Caution recommended for patients with chronic sinus disease, frequent chest infections, or low FEV1 included in guideline exclusions.
    • Authorization requests should address guideline recommendations and provide supporting documentation.
    Documentation Required

    Procedure should only be done in specialist centers

    Procedure should only be performed by trained clinicians in specialist centers with multidisciplinary oversight and on‑site intensive care access. Appropriate training and experience should be documented.

    • Specialist center with multidisciplinary team and ICU access required.
    • Document clinician training and experience with BT.
    • Centers should have governance, consent, and audit processes in place.
    Note

    Authorization and step‑therapy administrative notes

    While guidelines and some registries support registry‑based use, there are no explicit Aetna prior authorization or step‑therapy requirements specified in this policy text. Providers should include complete documentation to facilitate authorization review.

    • No explicit prior authorization criteria or step‑therapy sequence are specified in the policy text.
    • No step‑therapy requirements are specified here; authorization decisions will be handled per payer process and experimental/investigational designation.
    • Providers should supply full clinical documentation to support any authorization requests.
    Billing Rule

    Procedure documentation & coding

    Include detailed procedural and coding documentation with any claim or authorization request. Relevant CPT codes include 31660 (bronchoscopy with bronchial thermoplasty, 1 lobe) and 31661 (2 or more lobes). Provide bronchoscopy details, number of lobes treated, dates of each session, anesthesia/sedation, and any intra‑ or post‑procedural complications.

    • Report CPT 31660 (1 lobe) or 31661 (2+ lobes) as applicable.
    • Include bronchoscopy details (procedure dates, number of sessions — typically three, lobes treated).
    • Document anesthesia/sedation, conscious sedation vs general anesthesia, and peri‑procedural events.
    Documentation Required

    Suggested Clinical Documentation

    Suggested clinical documentation to accompany requests or registry entry includes baseline spirometry (FEV1, FVC), bronchodilator responsiveness, AQLQ and ACT scores, medication history (including doses of ICS, LABA, OCS, biologics), history of exacerbations/hospitalizations/ED visits in prior 12 months, comorbidities, and rationale for BT selection.

    • Baseline FEV1, FVC, and bronchodilator reversibility.
    • AQLQ and ACT scores at baseline.
    • Medication history and doses (high‑dose ICS, LABA, other controllers, biologics, maintenance OCS).
    • History of severe exacerbations, ED visits, and hospitalizations in prior 12 months.
    • Rationale for choosing BT (failed optimized therapy, phenotype considerations, specialist assessment).
    Documentation Required

    Histologic and clinical follow‑up data collection

    When available, histologic and immunohistochemical follow‑up data (airway smooth muscle mass, collagen deposition) and clinical outcomes should be collected and submitted to registries or included in follow‑up reports to support ongoing evaluation of BT safety and effectiveness.

    • Collect histologic data where clinically obtained (airway biopsy results showing ASM changes) and summarize findings.
    • Collect and report clinical follow‑up: exacerbation rates, hospitalizations, ED visits, spirometry, medication changes, AQLQ/ACT.
    Documentation Required

    Clinicians should enter details of all patients into registries

    Clinicians should enter details of all patients undergoing BT into established registries (for example, the UK Severe Asthma Registry or other IRB‑approved registries) when feasible, and document consent, patient selection criteria, and outcomes to support surveillance and future authorization considerations.

    • Registry entry: baseline characteristics, consent, ACT/AQLQ, medications, FEV1/FVC, 12‑month baseline exacerbation/utilization data.
    • Document long‑term outcomes and any adverse events in registry submissions.
    Note

    Administrative notes and policy links

    This portion of the policy includes administrative notes and links for review history, effective date, and additional information. Providers should consult the policy history and additional information sections for updates and payer‑specific administrative procedures.

    • Effective date: 2008‑02‑08; Next review noted in policy header.
    • Administrative links and clinical policy bulletin notes available for providers.
    Clinical contextStudied as a minimally invasive option for adults with severe, persistent asthma not controlled with standard medical therapy
    Alair Bronchial Thermoplasty System
    Device nameAlair Bronchial Thermoplasty System (Asthmatx Inc.)
    FDA-approved indicationTreatment of patients aged 18 years and older with severe persistent asthma not well-controlled with inhaled corticosteroids and long-acting beta-agonists
    Regulatory basisFDA approval (April 2010) based on AIR2 trial data and requirement for a 5-year post-approval study
    BT treatment sessions
    Treatment courseProcedure is delivered in three separate bronchoscopic sessions to treat all accessible airways in both lungs
    Interval between sessionsSessions are usually spaced at a minimum of three-week intervals
    Session settingTypically performed outpatient with conscious sedation; each session takes approximately one hour
    BT: endoscopic / radiofrequency explanation
    MechanismEndoscopic delivery of localized radiofrequency energy via a catheter passed through a bronchoscope
    Target tissueAims to ablate airway smooth muscle in the airway wall to reduce bronchoconstriction
    Catheter/electrodesCatheter tip expands to make contact with airway wall electrodes that deliver controlled thermal energy
    Specialist center: requirements
    Multidisciplinary teamSpecialist center: a multidisciplinary team with clinicians trained in BT and experience managing severe asthma
    On-site resourcesOn-site access to intensive care and arrangements for clinical governance, consent, and audit
    Data reportingClinicians should enter patient details onto a registry (e.g., UK Severe Asthma Registry) and report patient selection and long-term outcomes
    Severe asthma (GINA / ERS-ATS criteria)
    Severity definitionSevere asthma: asthma requiring Step 4 or 5 therapy per GINA or meeting ERS/ATS criteria—uncontrolled despite high-intensity inhaled therapy
    Prior therapyPatients typically require optimization on high-dose inhaled corticosteroids plus long-acting beta-agonists and other controller therapies before consideration
    Selection contextGuidelines advise BT only for adults within IRB-approved registries or clinical studies and after specialist referral
    Bronchial thermoplasty (short definition)
    Concise definitionA bronchoscopic device-based procedure that applies controlled thermal (radiofrequency) energy to airway walls to reduce smooth muscle mass
    PurposeIntended to decrease airway hyperresponsiveness and reduce severe exacerbations in selected patients with severe asthma
    Typical patient ageDeveloped for and studied in adults aged 18 years and older
    Definitions: administrative note
    Administrative noteThis policy segment does not contain formal glossary definitions here; a separate Definitions link is referenced for official terms
    Policy referencesProviders should consult the policy's Definitions page for formal term definitions and administrative details
    Scope of this documentThis Clinical Policy Bulletin provides coverage stance, clinical context, and references but points to a dedicated Definitions resource for formal definitions